Involvement of ET-1 in diabetic cardiomyopathy, vascular abnormality and nepropathy which are regressed by a novel endothelin receptor antagonist Dajisentan.

AIM: An impaired endothelium contributes to diabetic cardiomyopathy (CMP), vascular pathy (VSP) and nephropathy (NPP) in diabetes. It is hypothesized that these disorders which are the consequence to damaged endothelium could be recovered by Dajisentan, a novel dual endothelin receptor antagonist, developed by us as an investigated new drug. METHODS: Rat diabetes model was developed by ip streptozotocin and the     

Over-phosphorylation of FKBP12.6, phospholamban,relating to exacerbation of cardiac arrhythmias and failure

AIM: Cardiac arrhythmias occur severely in diseased and failing hearts and remain an important cause of mortality in cardiovascular disorders. It was intended to explore mechanisms of abnormal ion channels underlying cardiac arrhythmias and failure and in responses to drug interventions. METHODS: Chronic infarction plus isoproterenol (ISO) medication or L-thyroxin (THY) repetitive medication promote cardiac remodeling and exaggerated